• 1
    White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I48.
  • 2
    Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 1997; 126: 4547.
  • 3
    Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005; 11: 66373.
  • 4
    MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006; 63: S515.
  • 5
    Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007; 13: 47586.
  • 6
    Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S, Pashos CL, Cohen AT. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6: 5974.
  • 7
    Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Ginsberg JS. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 2008; 6: 110512.
  • 8
    Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698707.
  • 9
    Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006; 24: 86990.
  • 10
    Statistics Canada. [Internet]. Table 326-0021. Consumer price index. CANSIM database. Accessed 29 March 2010.
  • 11
    Lim ME, Bowen JM, O’Reilly D, McCarron CE, Blackhouse G, Hopkins R, Goeree R, Tarride JE. Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literature. Value Health 2010; 13: 32834.
  • 12
    Bank of Canada. Accessed 1 December 2010.
  • 13
    El-Hadi W, Johri M, Kahn SR. Acceptability and validity of use of a patient-reported cost diary to capture health resource utilization and costs associated with deep venous thrombosis and post-thrombotic syndrome. Blood 2007; 110: 5173.
  • 14
    Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 32740.
  • 15
    Canadian Automobile Association. [Internet]. Accessed 21 July 2010.
  • 16
    Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 100510.
  • 17
    Statistics Canada. Labour Force Historical Review 2008 (Table Cd1T26an). Accessed 30 July 2010.
  • 18
    Statistics Canada. Table 282-0069. CANSIM database. Accessed 30 July 2010.
  • 19
    Contandriopoulos AP. Guidelines for the Economic Evaluation of Health Technologies. Canada: Canadian Agency for Drugs and Technologies in Health (CADTH), 2006.
  • 20
    Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999; 20: 12544.
  • 21
    Commission des normes du travail au Québec. [Internet]. Accessed 11 August 2010.
  • 22
    Roldan V, Lecumberri R, Munoz-Torrero JF, Vicente V, Rocha E, Brenner B, Monreal M. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res 2009; 124: 1747.
  • 23
    Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S545S.
  • 24
    Spirk D, Husmann M, Willenberg T, Banyai M, Frank U, Baldi T, Amann-Vesti B, Baumgartner I, Kucher N. Inconsistencies in the planning of the duration of anticoagulation among outpatients with acute deep-vein thrombosis. Results from the OTIS-DVT Registry. Thromb Haemost 2011; 105: 23944.
  • 25
    Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 5236.
  • 26
    Jonsson L, Eliasson A, Kindblom J, Almgren O, Edvardsson N. Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany. Appl Health Econ Health Policy 2010; 8: 31725.
  • 27
    Migliaccio-Walle K, Caro JJ, Ishak KJ, O’Brien JA. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharmacoeconomics 2005; 23: 73342.